PT2489731E - Enzimas aciltransferase de lecitina-colesterol modificadas - Google Patents
Enzimas aciltransferase de lecitina-colesterol modificadas Download PDFInfo
- Publication number
- PT2489731E PT2489731E PT12003811T PT12003811T PT2489731E PT 2489731 E PT2489731 E PT 2489731E PT 12003811 T PT12003811 T PT 12003811T PT 12003811 T PT12003811 T PT 12003811T PT 2489731 E PT2489731 E PT 2489731E
- Authority
- PT
- Portugal
- Prior art keywords
- cholesterol acyltransferase
- modified lecithin
- acyltransferase enzymes
- enzymes
- lecithin
- Prior art date
Links
- 102000014190 Phosphatidylcholine-sterol O-acyltransferase Human genes 0.000 title 1
- 108010011964 Phosphatidylcholine-sterol O-acyltransferase Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1025—Acyltransferases (2.3)
- C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y203/00—Acyltransferases (2.3)
- C12Y203/01—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
- C12Y203/01043—Phosphatidylcholine-sterol O-acyltransferase (2.3.1.43), i.e. lecithin-cholesterol acyltransferase or LCAT
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95200707P | 2007-07-26 | 2007-07-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2489731E true PT2489731E (pt) | 2014-09-15 |
Family
ID=39864722
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT12003811T PT2489731E (pt) | 2007-07-26 | 2008-07-25 | Enzimas aciltransferase de lecitina-colesterol modificadas |
PT08796592T PT2181190E (pt) | 2007-07-26 | 2008-07-25 | Enzimas aciltransferase de lecitina-colesterol modificadas |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT08796592T PT2181190E (pt) | 2007-07-26 | 2008-07-25 | Enzimas aciltransferase de lecitina-colesterol modificadas |
Country Status (26)
Country | Link |
---|---|
US (3) | US8168416B2 (pt) |
EP (4) | EP2489731B1 (pt) |
JP (5) | JP5643643B2 (pt) |
KR (1) | KR20100040937A (pt) |
CN (1) | CN101855344B (pt) |
AU (1) | AU2008279065B2 (pt) |
BR (1) | BRPI0814310A2 (pt) |
CA (1) | CA2694590A1 (pt) |
CR (1) | CR11272A (pt) |
CY (2) | CY1114857T1 (pt) |
DK (2) | DK2489731T3 (pt) |
EA (1) | EA201070187A1 (pt) |
ES (3) | ES2449483T3 (pt) |
HK (1) | HK1138039A1 (pt) |
HR (1) | HRP20140315T1 (pt) |
IL (1) | IL203399A0 (pt) |
MX (1) | MX348799B (pt) |
MY (1) | MY159075A (pt) |
NZ (2) | NZ597885A (pt) |
PL (2) | PL2489731T3 (pt) |
PT (2) | PT2489731E (pt) |
RS (1) | RS53237B (pt) |
SG (1) | SG186016A1 (pt) |
SI (2) | SI2181190T1 (pt) |
UA (1) | UA103304C2 (pt) |
WO (1) | WO2009015314A2 (pt) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2449483T3 (es) * | 2007-07-26 | 2014-03-19 | Amgen, Inc | Enzimas lecitina-colesterol aciltransferasa modificadas |
CA2764189C (en) * | 2009-06-12 | 2019-04-30 | Alphacore Pharma Llc | Use of lcat for treating anemia and red blood cell dysfunction |
EP2566505B1 (en) * | 2010-05-06 | 2019-10-16 | Alphacore Pharma LLC | Delivery of cholesteryl ester to steroidogenic tissues |
EP2701732B1 (en) * | 2011-02-25 | 2017-08-30 | University Of Patras | Lecithin:cholesterol acyltransferase (lcat) and its role in nonalcoholic fatty liver disease (nafld) |
RU2639521C2 (ru) * | 2011-05-05 | 2017-12-21 | ВЕЛЛСТАТ ИММЬЮНОТЕРАПЬЮТИКС, ЭлЭлСи | Аналоги фактора комплемента в и их применения |
EP2788384B1 (en) | 2011-12-08 | 2017-08-09 | Amgen Inc. | Agonistic human lcat antigen binding proteins and their use in therapy |
US10583104B2 (en) * | 2014-08-06 | 2020-03-10 | Indiana University Research And Technology Corporation | Tuneable delivery of nanoparticle bound active plasmin for the treatment of thrombosis |
WO2016123569A2 (en) * | 2015-01-29 | 2016-08-04 | Plantvax, Inc. | Highly expressed protective plant-derived broadly neutralizing hiv monoclonal antibodies for use in passive immunotherapy |
WO2018022511A1 (en) | 2016-07-25 | 2018-02-01 | The Trustees Of The University Of Pennsylvania | Compositions comprising a lecithin cholesterol acyltransferase variant and uses thereof |
CN111601614A (zh) * | 2017-11-07 | 2020-08-28 | 阿尔法科制药有限责任公司 | 治疗和预防心脏病、心血管疾病及相关病症和症状的方法 |
EA202092799A1 (ru) * | 2018-05-22 | 2021-03-01 | ДСМ АйПи АССЕТС Б.В. | Модифицированные стерол-ацилтрансферазы |
US11612619B2 (en) | 2018-11-01 | 2023-03-28 | National Institute Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs), U.S. Government | Compostions and methods for enabling cholesterol catabolism in human cells |
KR200493485Y1 (ko) * | 2019-08-27 | 2021-04-07 | 주식회사 서원기술 | 배관용 고무링 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3691016A (en) | 1970-04-17 | 1972-09-12 | Monsanto Co | Process for the preparation of insoluble enzymes |
CA1023287A (en) | 1972-12-08 | 1977-12-27 | Boehringer Mannheim G.M.B.H. | Process for the preparation of carrier-bound proteins |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US3941763A (en) | 1975-03-28 | 1976-03-02 | American Home Products Corporation | PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates |
US4195128A (en) | 1976-05-03 | 1980-03-25 | Bayer Aktiengesellschaft | Polymeric carrier bound ligands |
US4330440A (en) | 1977-02-08 | 1982-05-18 | Development Finance Corporation Of New Zealand | Activated matrix and method of activation |
CA1093991A (en) | 1977-02-17 | 1981-01-20 | Hideo Hirohara | Enzyme immobilization with pullulan gel |
US4229537A (en) | 1978-02-09 | 1980-10-21 | New York University | Preparation of trichloro-s-triazine activated supports for coupling ligands |
US4289872A (en) | 1979-04-06 | 1981-09-15 | Allied Corporation | Macromolecular highly branched homogeneous compound based on lysine units |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US5354772A (en) | 1982-11-22 | 1994-10-11 | Sandoz Pharm. Corp. | Indole analogs of mevalonolactone and derivatives thereof |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
AR240698A1 (es) | 1985-01-19 | 1990-09-28 | Takeda Chemical Industries Ltd | Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
JPS63167409A (ja) | 1986-12-27 | 1988-07-11 | Yamaha Corp | 磁気記録体 |
US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
AU610083B2 (en) | 1986-08-18 | 1991-05-16 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
US5229490A (en) | 1987-05-06 | 1993-07-20 | The Rockefeller University | Multiple antigen peptide system |
EP0842925A1 (en) | 1987-09-04 | 1998-05-20 | Beecham Group Plc | Substituted thiazolidinedione derivatives |
US6288095B1 (en) | 1987-09-04 | 2001-09-11 | Beecham Group P.L.C. | Compounds |
ATE106249T1 (de) | 1987-11-05 | 1994-06-15 | Hybritech Inc | Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. |
GB8824591D0 (en) | 1988-10-20 | 1988-11-23 | Royal Free Hosp School Med | Fractionation process |
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
AU643141B2 (en) | 1991-03-15 | 1993-11-04 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
HU9203780D0 (en) | 1991-12-12 | 1993-03-29 | Sandoz Ag | Stabilized pharmaceutical products of hmg-coa reductase inhibitor and method for producing them |
ATE156158T1 (de) | 1992-04-14 | 1997-08-15 | Cornell Res Foundation Inc | Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung |
US5792451A (en) | 1994-03-02 | 1998-08-11 | Emisphere Technologies, Inc. | Oral drug delivery compositions and methods |
US5741803A (en) | 1992-09-05 | 1998-04-21 | Smithkline Beecham Plc | Substituted thiazolidinedionle derivatives |
JP3254219B2 (ja) | 1993-01-19 | 2002-02-04 | ワーナー−ランバート・コンパニー | 安定な経口用のci−981製剤およびその製法 |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
TW438587B (en) | 1995-06-20 | 2001-06-07 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
PL193479B1 (pl) | 1995-07-17 | 2007-02-28 | Warner Lambert Co | Formy krystaliczne hydratu atorwastatyny, kompozycja farmaceutyczna zawierająca formę krystaliczną I hydratu atorwastatyny oraz jej zastosowanie |
EP0871713B1 (en) * | 1995-11-09 | 2007-02-14 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | The use of lecithin-cholesterol acyltransferase (lcat) in the treatment of atherosclerosis |
EP0904107B1 (en) | 1996-03-18 | 2004-10-20 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
FR2758459B1 (fr) | 1997-01-17 | 1999-05-07 | Pharma Pass | Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation |
CA2284832A1 (en) * | 1997-04-11 | 1998-10-22 | Takeda Chemical Industries, Ltd. | Proteins having lecithin-cholesterol acyltransferase-like activity, their production and use |
DE69818444T2 (de) | 1998-07-15 | 2004-05-06 | Merck Santé | Tabletten enthaltend eine Kombination von Glibenclamid und Metformin |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
AU5931600A (en) | 1999-07-14 | 2001-02-05 | Betagene, Inc. | Lcat recombinant cell line compositions and methods |
US20080096900A1 (en) * | 2006-06-26 | 2008-04-24 | Amgen Inc. | Methods for treating atherosclerosis |
ES2449483T3 (es) * | 2007-07-26 | 2014-03-19 | Amgen, Inc | Enzimas lecitina-colesterol aciltransferasa modificadas |
-
2008
- 2008-07-25 ES ES08796592T patent/ES2449483T3/es active Active
- 2008-07-25 DK DK12003811T patent/DK2489731T3/en active
- 2008-07-25 PL PL12003811T patent/PL2489731T3/pl unknown
- 2008-07-25 AU AU2008279065A patent/AU2008279065B2/en not_active Ceased
- 2008-07-25 KR KR1020107003535A patent/KR20100040937A/ko not_active Application Discontinuation
- 2008-07-25 ES ES12003811.2T patent/ES2513716T3/es active Active
- 2008-07-25 RS RSP20140148 patent/RS53237B/en unknown
- 2008-07-25 PT PT12003811T patent/PT2489731E/pt unknown
- 2008-07-25 SG SG2012085213A patent/SG186016A1/en unknown
- 2008-07-25 UA UAA201002094A patent/UA103304C2/ru unknown
- 2008-07-25 MY MYPI2010000370A patent/MY159075A/en unknown
- 2008-07-25 EA EA201070187A patent/EA201070187A1/ru unknown
- 2008-07-25 PL PL08796592T patent/PL2181190T3/pl unknown
- 2008-07-25 SI SI200831169T patent/SI2181190T1/sl unknown
- 2008-07-25 US US12/179,815 patent/US8168416B2/en active Active
- 2008-07-25 SI SI200831324T patent/SI2489731T1/sl unknown
- 2008-07-25 EP EP20120003811 patent/EP2489731B1/en active Active
- 2008-07-25 ES ES12003810.4T patent/ES2559353T3/es active Active
- 2008-07-25 MX MX2014001593A patent/MX348799B/es unknown
- 2008-07-25 DK DK08796592T patent/DK2181190T3/da active
- 2008-07-25 CA CA 2694590 patent/CA2694590A1/en not_active Abandoned
- 2008-07-25 NZ NZ59788508A patent/NZ597885A/xx not_active IP Right Cessation
- 2008-07-25 JP JP2010518400A patent/JP5643643B2/ja not_active Expired - Fee Related
- 2008-07-25 EP EP12003809.6A patent/EP2522721B1/en active Active
- 2008-07-25 EP EP12003810.4A patent/EP2489730B1/en active Active
- 2008-07-25 NZ NZ58279408A patent/NZ582794A/xx not_active IP Right Cessation
- 2008-07-25 EP EP20080796592 patent/EP2181190B1/en active Active
- 2008-07-25 PT PT08796592T patent/PT2181190E/pt unknown
- 2008-07-25 WO PCT/US2008/071119 patent/WO2009015314A2/en active Application Filing
- 2008-07-25 CN CN200880109092.XA patent/CN101855344B/zh not_active Expired - Fee Related
- 2008-07-25 BR BRPI0814310 patent/BRPI0814310A2/pt not_active Application Discontinuation
-
2010
- 2010-01-19 IL IL203399A patent/IL203399A0/en unknown
- 2010-02-12 CR CR11272A patent/CR11272A/es unknown
- 2010-05-13 HK HK10104660A patent/HK1138039A1/xx not_active IP Right Cessation
-
2012
- 2012-04-04 US US13/439,428 patent/US8703926B1/en active Active
-
2014
- 2014-02-18 CY CY20141100119T patent/CY1114857T1/el unknown
- 2014-03-04 US US14/196,827 patent/US9006408B2/en active Active
- 2014-04-01 HR HRP20140315AT patent/HRP20140315T1/hr unknown
- 2014-06-25 JP JP2014130551A patent/JP6033258B2/ja not_active Expired - Fee Related
- 2014-09-19 CY CY20141100767T patent/CY1115573T1/el unknown
-
2016
- 2016-06-23 JP JP2016124506A patent/JP2016182136A/ja active Pending
-
2018
- 2018-06-05 JP JP2018107669A patent/JP2018161134A/ja active Pending
-
2019
- 2019-12-18 JP JP2019228172A patent/JP2020058366A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1138039A1 (en) | Modified lecithin-cholesterol acyltransferase enzymes | |
HK1148519A1 (en) | Diacylglycerol acyltransferase inhibitors | |
GB0719620D0 (en) | Mutant Enzymes | |
HUE036318T2 (hu) | Módosított foszfatázok | |
EP2169055A4 (en) | NEW LYSOPHOSPHATIDATE ACYLTRANSFERASE GENE | |
PL2017352T3 (pl) | Sensor elektrochemiczny z kowalencyjnie związanym enzymem | |
EP2119781A4 (en) | Glyceroglycolipid LIPASE | |
EP2467477A4 (en) | FAST-ACTING SNARE-COLUMN ENZYMES | |
EP2192402A4 (en) | ENZYME ELECTRODE | |
GB0804721D0 (en) | Enzyme | |
GB0818328D0 (en) | Novel enzyme | |
ZA201107395B (en) | Enzyme with silaffin | |
GB0803628D0 (en) | Enzyme | |
EP1997896A4 (en) | GENEIGNING AND LIGNAN METHYLATING ENZYME | |
GB0804722D0 (en) | Enzyme | |
IL207848A0 (en) | Artificial enzymes | |
GB0800831D0 (en) | Enzymes 1 | |
GB0617387D0 (en) | Synthetic gene | |
HU0600159D0 (en) | Kvantitative pcr | |
GB0716735D0 (en) | Insert stove | |
GB2467284B (en) | Sulfatase enzymes | |
GB0711246D0 (en) | Enzyme | |
GB0711245D0 (en) | Enzyme | |
GB0713609D0 (en) | Enzyme | |
GB0713610D0 (en) | Enzyme |